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Our investigation of the therapeutic effectiveness of calciferol (vitamin D2)
for various tuberculoderms, sarcoidosis, granuloma annulare, psoriasis and
lichen planus was started a few months after Charpy, and Dowling and Thomas
published their results with this agent. Lichen planus was included because of
the favorable results reported by Charpy; and psoriasis because of the incon-
clusive results of earlier reports of therapeutic trials with vitamin D.
The study was continued over a period of two years, through the summer of
1948 in order to obtain a sufficient number of tuberculoderms (since these derma-
toses are not prevalent in this country) and in order to afford an opportunity
for periodic "follow-up" examinations after termination of treatment. In addi-
tion to ascertaining the therapeutic value of calciferol, we planned to compare
the Charpy and the Dowling and Thomas methods of administration of D2
and to determine, if possible, whether or not there may be any variation in the
tolerance for, or the toxic effects of, the two different preparations of calciferol
employed. Four staff members participated in this study under the direction
of Dr. Frances Pascher, in charge of the treatment unit of the New York Skin
and Cancer Unit, New York Post Graduate Medical School and Hospital.
CASE MATERIAL
Calciferol was administered to 77 patients, all of whom were ambulatory and
all of whom were examined to exclude cardiovascular and renal disease before
treatment was started. Pregnancy was also considered a contraindication to the
administration of this drug.
The following dermatoses were treated:
I Tuberculosis cutis—total number of cases 14
Tuberculosis luposa (lupus vulgaris) 12
Tuberculosis coiliquativa (scrofuloderma) 2
II Tuberculids—totai number of cases 10
Lupus miii aris disseminatus faciei 5
Tuberculid (rosaeea-like-Lewandowsky) 1
Tuberculid (of the face—not classifiable) 1
Tuberculosis indurativa (erythema induratum) 3
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III Sarcoidosis—total number of cases 7
Cutaneous (Boeck' 3
Generalized (Schaumann) 4
IV Granuloma annulare—total number of cases 5
V Psoriasis—total number of cases 27
VI Lichen planus—total number of cases 14
Total number of cases 77
METHOD OF TREATMENT
The "methode Charpy" was adhered to in approximately one third of the
cases, the Dowling and Thomas technic in another third. For the rest, the Charpy
and the Dowling and Thomas plans of treatment were alternated.
In order to duplicate as exactly as possible the original procedure of Charpy
we obtained and used a specially prepared solution of Vitamin D2. This solution
of crystalline vitamin D2 (Drisdol) was prepared according to our specification
and supplied for this study by Winthrop-Stearns, Inc. to whom we are indebted
for their splendid cooperation. It may be assumed that this crystalline prepara-
tion of D2, made by the activation of ergosterol by ultraviolet rays and purified
by separation from other sterols, is chemically and biologically identical with
crystalline D2 (Sterogyl 15) prepared by Roussel Laboratories (Paris) for Dr.
Charpy. The same solvent, i.e. 90% ethanol, the same concentration, namely
15 mg. or 600,000 units per 2 cc. of solution, and the same dosage as used by
Charpy, were used. Forty-five mg. or 1,800,000 units were administered the
first week, 30 mg. or 1,200,000 units the second, third and fourth weeks, and a
maintenance dose of 15 mg. or 600,000 units weekly thereafter. Calcium glu-
conate, 1 Gm. daily, was administered early in the course of therapy, and was
discontinued later when Feeney, Sandiland and Franklin showed that calcium
salts were not essential to the treatment. Moreover, the reduction of intake of
calcium salts seemed desirable since "the administration of larger quantities of
calcium salts increases the tendency toward the production of hypercalcemia"
(Cantarow and Trumper). No restrictions in diet were made other than to limit
the milk intake to one pint daily, to eliminate cheese and to interdict the inges-
tion of aperients (mineral oil and mineral oil emulsions).
The second method of therapy employed more closely resembled the treatment
outlined by Dowling. In this plan high potency vitamin D2 capsules, containing
50,000 units of D2 per capsule were administered three times a day for a period
of a few months and twice a day thereafter. Dowling and Thomas used a prepa-
ation of D2 known as Orstelin (Glaxo Laboratories) high potency tablets con-
taining 50,000 units. Calciferol prepared by the activation of ergosterol by low
velocity electrons (Davitin, Ives-Cameron, Inc.) was selected for the present
study. The dietary restrictions imposed were the same as for the group treated
with crystalline D2 (Drisdol) in alcohol.
In most cases an average dose of 100,000 units per day of either preparation
of D2 was maintained unless symptoms or signs of intoxication appeared. In a













Twelve cases of lupus vulgaris were treated. All but one were typical, char-
acterized by chronicity (duration 10-30 years) "apple-jelly nodules", discrete or
in plaques of varying size and associated with variable degrees of scarring.
Among the eleven typical cases, there were two also showing lupus tumidans,
one also showing lupus vulgaris verrucosus of the palm, and one with lupus vul-
garis combined with lupus miliaris disseminatus faciei. In two cases there was
evidence of arrested or healed tuberculosis of another organ. One showed arrested
pulmonary tuberculosis and the other a healed anterior nasal septum perforation
and scars on the cornea. Because of its short duration and because of an associated
tuberculin anergy the twelfth case was considered atypical or transitional, de-
spite the histologic diagnosis of lupus vulgaris.
Improvement was noted as early as three weeks in three cases, and not until
the third month in two cases. The healing time was six and seven months re-
spectively in two cases, nine months in one case and eleven months to a year in
three cases. (The atypical case was healed in two months). The healed cases
have been followed for periods varying from two months to one year. Two suffered
a relapse. In one case, the presumably healed lesions appeared somewhat elevated
again seven months after treatment had been discontinued. Treatment was re-
sumed in this case and after 100,000 units of D2 daily for two weeks, the lesions
regressed and have remained quiescent during a second "follow-up" period of
five months. In the second case, the relapse occurred in a ten year old child, who
returned ten weeks after treatment had been discontinued, presenting two small
nodules in a previously healed site. The response to the second course of D2 was
slower than the first. Whereas healing appeared to be complete after seven months
of the first course, the lesions showed only partial regression after six months of
a second course.
In both cases of lupus tumidans the lesions responded dramatically to treat-
ment. The inflammatory reaction began to subside during the first month, and
resolution was progressive during the entire period of treatment. Nevertheless,
healing was still incomplete at the end of a year in both cases. The results in
lupus tumidans may be rated as good since approximately 75—96% improvement
was attained. The verrucous lesion noted in one case healed after four months
of therapy and remained healed during an observation period of more than a
year.
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Little or no improvement was obtained in three of the typical cases of lupus
vulgaris. Irregularities in dosage may have accounted for the poor results in one
but there was no apparent reason to explain the poor results in the other two.
There were no notable differences in the results obtained with D2 in alcohol
(Drisdol-Winthrop-Stearns) and equivalent doses of D2 in oil (Davitin-Ives-
Cameron). Six cases were treated with the alcoholic solution of D2 and six were
treated with both preparations, alternately. It may also be noted here, that
there was no evidence of activation of the healed or arrested tuberculous pro-
cesses of other organs.
TABLE II
Tuberculosis colliquativa (scrofuloderma)
Tuberculosis colliquativa—total number of cases 2
Improvement (good) 2/2
DISCUSSION
Improvement was noted as early as two weeks in one case and within two
months in the other. One case remained under treatment a little less than five
months. Within that time, a large linear plaque over Poupart's ligament had
healed completely and another palm sized plaque on the left thigh was not quite
completely healed. The second patient improved slowly while taking 50,000
units a day. After the dose was increased to 150,000 units daily, the improvement
was striking within a month and the lesions were almost completely healed after
four months of the higher dosage.
TABLE III
Lu pus m'iliaris di.sseniinatus faciei







The healed case was treated for a period of thirteen weeks. There was no ap-
preciable improvement in this case however until the dosage was increased from
150,000 units of D2 in alcohol to 250,000 units per day. The lesions in the case
associated with lupus vulgaris regressed considerably but were not quite healed
after one year of treatment. The case in which the response was rated as fair
was treated for six weeks. The patient continued to improve after treatment was
discontinued, all lesions healing within two months after treatment was stopped.
In one case the condition remained unimproved after six months of treatment
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and in the fifth case the eruption spread, becoming more inflammatory during
the eighth month of treatment.
TABLE IV
Tuberculids of the face
Tuberculid of the face (unclassified)—number of cases 1
Unimproved 1
New lesions continued to appear after three months of treatment.
TABLE V
Tuberculid (rosacea-like-Lewandowsky)
Tuberculid (rosacea-like-Lewandowsky)—number of cases 1
Healed 1/1
100,000—L50,000 units of D2 (Davitin-Ives-Cameron, Inc.) was administered daily for a
period of four months.
TABLE VI
Tuberculosis indurativa (erythema induratum Bazin)
Tuberculosis indurativa—number of cases 3
Healed 1/3
Worse 2/3
The ulcers healed within three months in one of these cases, but it was three months more
before the erythema and induration subsided. There was no recurrence during an eight
month "follow-up" period. Two grew progressively worse while under treatment, carried
out for six weeks in one case and eight weeks in the other.
TABLE VII
Sarcoidosis (cutaneous and generalized)




In one case of Boeck's sarcoid, the lesions were somewhat flatter after two
months of treatment. The patient failed to return, making evaluation of the
results in this case difficult.
Of the six patients who failed to improve, as far as could be discovered, two had
sarcoidosis of the skin alone and four had visceral involvement as well. Treatment
was continued for one year in one case, and from three to six months in the
others. One patient in this group, who was given less than the average dose
(36,000—48,000 units daily for three months) because of intolerance to the medi-
cation, began to improve after treatment was stopped. This patient, who had
visceral as well as cutaneous sarcoidosis for two years, was free of the eruption
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six months after therapy was discontinued. The relatively poor results in our
series stand in some contrast to the relatively good results reported by others.
TABLE VIII
Granuloma an,nutare





In one case the lesions regressed while under treatment only to recur as soon
as treatment was discontinued. This was observed with each of three consecutive
trials of the drug. In a second case the lesion remained unchanged after thirteen
weeks of treatment. However, three of five patients grew worse. In one the erup-
tion became more evident, the lesions extending peripherically. Two patients
developed a widespread dissemination of the eruption during the third and sixth
weeks of treatment. One of these lesions was excised and was examined histo-
logically. Changes typical of granuloma annulare were found.
TABLE IX
Psoriasis







Treatment was carried out for a minimum of four weeks and not longer than eight weeks.
TABLE X
Lichen planus





These patients were treated for a minimum of four weeks. In eight cases treatment was
continued for ten to fourteen weeks. Among the healed cases there was one bullous eruption
that responded dramatically.
TOXICITY
The toxic manifestation attributable to calciferol therapy may be grouped
under two headings: 1) symptoms of toxicity and 2) chemical manifestations of
toxicity.
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Of the 77 patients treated ten developed one or more of the following symptoms.
Nausea 4 Frequency of urination 3
Abdominal pain 3 Thirst 2
Vomiting 2 Nocturia 1
Loss of appetite 1 Loss of weight 1
Fatigue and weakness 2 Joint pains 1
The symptoms appeared during the first week of treatment in one case; during
the second week of treatment in one case; during the third week of treatment
in one case; during the fifth week of treatment in one case; during the second
month of treatment in three cases; during the third month of treatment in two
cases and during the fifth month of treatment in one case.
The subjective symptoms were relieved within a week or two after treatment
was discontinued. After a rest period of one to three months, average doses were
well tolerated by four of the six patients who resumed treatment. One patient
(with generalized sarcoidosis) could not take more than 36,000 units a day. The
other showed evidence of renal irritation before symptoms of toxicity reappeared.
Hypercalcemia was found in 16 out of 27 cases examined at intervals. An ele-
vation of the total serum calcium (above 12 mg.%) was first observed during the
second month of treatment in six cases, during the third month in two cases,
during the fifth month in two cases and not until the tenth month in one case.
This abnormal rise occurred in four (out of 10) true tuberculoderms, in six (out of
6) sarcoids and in five (out of 10) of the lichen planus—psoriasis group. The
highest figure, 15.3 mg. %, was reported in a case of sarcoidosis.
Treatment was discontinued when a rise above 12 mg. % of total calcium was
obtained. In four cases, serum calcium determinations were made, at intervals
after treatment was stopped. Normal figures were obtained after a rest period of
three weeks in one, but not until three months in three cases. Treatment was
resumed (approximately 100,000 units a day when normal values were obtained)
and was continued for two additional months in two cases, and nine months in
a third case without a subsequent rise in the serum calcium. In the fourth case,
however, the level again rose to 13.7 mg. %after two months of additional treat-
ment.
A correlation between the development of hypercalcemia and other signs and
symptoms of toxicity was attempted. Of the 16 patients with hypercalcemia, only
three had subjective symptoms that coincided with the elevation in the calcium.
One patient complained of fatigue, one of nausea, and the third of frequency,
thirst and nocturia. In one case the rise preceded the development of subjective
symptoms by one month, and in another case gastro-intestinal symptoms pre-
ceded the hypercalcemia by seven months. Eleven patients, therefore, had hyper-
calcemia without experiencing any discomfort prior to, at the time of, or sub-
sequent to the altered blood chemistry. Routine urine analyses gave consistently
normal results in thirteen cases. Albuminuria and granular casts were present
in three cases.
A total of 56 alkaline phosphatase determinations were made in 20 cases.
An insignificant rise to 6—7 units (normal 3—5 Bodansky units) was found in
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four cases. This rise was not accompanied either by hypercalcemia or by toxic
symptoms. An alkaline phosphatasemia, associated with a hypercalcemia was
found in two cases of sarcoidosis, 8.6 units in one case and 30.9 units in the other.
In the latter case, the initial report, two months after treatment had been started
was 10.2 units, a second report after three months of treatment was 27.0 units.
The highest determination 30.9 units was obtained one month after treatment
had been discontinued.
Fifty-three inorganic serum phosphate determinations were made in twenty-
five of the cases. A small transitory rise to 6.2 mg. % and 6.5 mg. % was found
on two occasions (normal values 3.5—4.0 mg. %).
A routine urine analysis was done at biweekly intervals in 45 cases. Five
patients developed an albuminuria (+—+++) during the course of treatment.
Red blood corpuscles in the urine were found concomitantly in four cases, leuko-
cytes in two cases, and a cylinduria in one case. The abnormal urinary findings
appeared during the first week of treatment in one case, during the third week in
another, at the end of one month in a third case, and not until the end of the
second month of treatment in a fourth case. All but one of these patients had
subjective symptoms. Two complained of nausea and vomiting, two of fatigue
and weakness, and another of thirst, frequency and nocturia. In the group were
two cases of sarcoidosis, two of erythema induratum and one of granuloma an-
nulare.
SUMMARY
The therapeutic results were gratifying in the "true tuberculoderms" (lupus
vulgaris and tuberculosis colliquativa), equivocal for the group of tuberculids,
and entirely disappointing in sarcoidosis.
Seventy-five per cent (8/12) of the cases of lupus vulgaris either healed or
were greatly improved, and both cases of tuberculosis colliquativa healed almost
completely.
Improvement was observed as early as two to three weeks in some cases and
not until the second or third month in others. The healing time was anywhere
between six and seven months to a year. In one case, one of lupus vulgaris in
which the relapse proved transitory, the lesions regressed after two weeks of
treatment; in a second case the nodules regressed only partially after six months
of continuous therapy.
In the group of "true tuberculoderms", we attempted to discover possible
correlations between the results of therapy and the age of the patient, or the
duration, extent of the involvement, or the degree of scarring. No apparent cor-
relation was present and no reason could be found for the lack of uniformity in
the results.
An optimum dose appeared to be 150,000 units of D2 daily.
The results with D2 in alcoholic solution (Drisdol) and with D2 in oil (Davitin)
appeared to be equally good. With the unintelligent patient, however, we felt
safer in dispensing the capsules, since an error in calculating the number of
"drops" would mean an error of 12,000 units per minim. Lack of uniformity in
CALCIFEROL 97
the size of the drops counted out by the patient would also mean considerable
variation in the dosage.
There was no uniformity in the results in the five cases of lupus miliaris dis-
seminatus faciei. One patient healed and another improved while under treat-
ment. A third patient healed two months after treatment was discontinued. On
the other hand, one patient failed to improve and another grew worse.
The favorable result in the single case of rosacea-like tuberculid of Lewandow-
sky is of course insufficient evidence for valid conclusions. Two of the three cases
of erythema induratum (Bazin's disease) grew progressively worse while under
treatment.
Contrary to the findings of some other observers, our results in sarcoidosis were
uniformly poor, both in the cutaneous 2nd the generalized form. In one out of
seven, the improvement was fair; the rest failed to improve to any perceptible
degree. One patient may possibly have benefited from the administration of D2.
Healing of the cutaneous manifestations after treatment was discontinued, may
possibly have been related to the previous ingestion of the drug.
D2 therapy proved to be detrimental in granuloma annulare. In three out of
five, the condition grew worse. In two, treatment was followed by a widespread
dissemination of the lesions.
The results in psoriasis and lichen planus were equivocal. More cases in the
psoriatic group failed to improve than were benefited. In the lichen planus group,
we were impressed with dramatic results in a case with bullous lesions.
Symptoms of toxicity appeared in ten of the 77 cases treated. The patients
complained of one or more of the following symptoms: nausea, vomiting, ab-
dominal pain, frequency of urination, thirst, nocturia, weakness or fatigue, loss
of weight, loss of appetite and joint pain. The time of onset of the symptoms
varied from one week to five months. In four out of six patients who had evi-
denced signs of intolerance, a later resumption of treatment demonstrated that
average doses (100,000—150,000 units of D2) were well tolerated after a rest
period of one to three months.
Hypercalcemia developed in approximately 60% (16/27) of the cases examined
at regular intervals. The rise in total serum calcium occurred as early as the
second month in some cases and not until the tenth month of treatment in one
case. Twenty-five per cent (4/16) of the patients experienced subjective symp-
toms during the period of hypercalcemia and 18% (3/16) showed urinary changes.
In three out of four cases it was possible to resume and continue D2 therapy
without a subsequent rise in the calcium level. Patients with sarcoidosis ap-
peared to be more susceptible than any other group. Each of the six patients
developed a hypercalcemia during the course of therapy, and the highest level
(15.3 mg. %) was obtained in this group.
No correlation was found between the alkaline phosphatase blood levels or
the inorganic serum phosphate blood levels with the development of toxic
symptoms or hypercalcemia. The deviations from the normal values for alkaline
phosphatase were insignificant except in one case of sarcoidosis. The high values
in the latter is attributed to the disease rather than to the treatment.
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Eleven per cent (5/45) of the patients examined developed urinary signs of
renal irritation during the course of therapy. The urinary changes appeared as
early as the first week in one and not until the end of the second month in another.
Subjective symptoms of toxicity were present in four out of five cases.
CONCLUSIONS
Our results fully substantiate the original claims of Charpy, and of Dowling
and Thomas, as well as those of later investigators, as to the therapeutic value
of high dosage calciferol (D2) therapy in lupus vulgaris and tuberculosis colliqua-
tiva. Equally good results were obtained with crystalline D2 (Drisdol) in alcohol
and with D2 (Davitin) in oil.
There was no uniformity in the response of certain tuberculids to this method
of treatment, and the results in psoriasis and lichen planus were equivocal.
The results in sarcoidosis were almost uniformly poor.
Oalciferol seemed harmful in granuloma annulare, since a wide-spread dis-
semination of the lesions appeared in two out of five cases treated.
The incidence of subjective symptoms of toxicity was 14%, of renal irritation
11%, and of hypercalcemia 60%. In the majority of cases symptoms of in-
tolerance appeared to be unrelated to the hypercalcemia.
A number of the patients who originally developed signs or symptoms of
toxicity showed what appeared to be increased tolerance for the drug when
treatment was resumed.
